Novel RAAS agonists and antagonists: clinical applications and controversies.
about
Sex differences in the aging pattern of renin-angiotensin system serum peptidases.An update of the blockade of the renin angiotensin aldosterone system in clinical practice.Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.Hypothalamic and inflammatory basis of hypertension.No substantial gender differences in suspected adverse reactions to ACE inhibitors and ARBs: results from spontaneous reporting system in Campania Region.Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system.Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin.Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.Captopril, an angiotensin-converting enzyme inhibitor, possesses chondroprotective efficacy in a rat model of osteoarthritis through suppression local renin-angiotensin system.Cooperative Oxygen Sensing by the Kidney and Carotid Body in Blood Pressure Control.Angiotensin-(1-7) counteracts the transforming effects triggered by angiotensin II in breast cancer cells.Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.A-type K+ channels contribute to the prorenin increase of firing activity in hypothalamic vasopressin neurosecretory neurons.Elevated serum fibrinogen level is an independent risk factor for IgA nephropathy.Sex-specific differences in age-dependent progression of aortic dysfunction and related cardiac remodeling in spontaneously hypertensive rats.Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer.Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium.
P2860
Q37624602-A8C13CB0-452E-4E23-AA7D-20BBD3E8775FQ38590227-0A9C6E68-4B88-4F30-93E9-76A8F87E8D81Q38592420-F3A9850A-2241-416A-B859-E4C91EB5B680Q38774292-D339069B-3E0B-4A1C-A927-58B5416BCE63Q39162849-7A3F9A27-F0CA-41FF-807D-974169B08777Q39224534-C89AEFEE-523C-483C-A288-52361465E288Q41168873-62E4BB71-244C-4537-85A2-91281FE3D222Q41410574-0CA9D723-5482-413B-BAD2-91C77505B78AQ41839983-92D6B898-862E-4C18-9977-1174275E3094Q42372768-B13CA2DA-23FF-48D5-A050-A90B57A3A483Q44861712-D438FCC8-ADD5-4ADC-9585-7B27285343C3Q46316918-04C5ED25-3348-436B-A0EE-531496A971BEQ46348355-F2619FEE-50EA-49C9-A1F6-2A43A91EA922Q47100563-5EAD4756-3345-4771-856F-ADBB4F8BFCDCQ47835264-1867D16E-ECF0-4F31-9859-9D55005FFB13Q47855049-83C51160-5B72-4FCB-9F4B-A4BC86B7900EQ50078700-19A449A1-C17B-4BC8-B3C0-0F5A2DBDB068
P2860
Novel RAAS agonists and antagonists: clinical applications and controversies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Novel RAAS agonists and antagonists: clinical applications and controversies.
@en
type
label
Novel RAAS agonists and antagonists: clinical applications and controversies.
@en
prefLabel
Novel RAAS agonists and antagonists: clinical applications and controversies.
@en
P2860
P356
P1476
Novel RAAS agonists and antagonists: clinical applications and controversies
@en
P2093
Marcelo Orias
Matthew R Weir
P2860
P2888
P304
P356
10.1038/NRENDO.2015.6
P577
2015-02-10T00:00:00Z